Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for preeclampsia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality.To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia.MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled Trials (January 2006 to June 2013 (...) ); previous systematic reviews, clinical trial registries, and surveillance searches for large studies (June 2013 to February 2014).Randomized, controlled trials (RCTs) to assess benefits among women at high preeclampsia risk and RCTs or large cohort studies of harms among women at any risk level. English-language studies of fair or good quality were included.Dual quality assessment and abstraction of studies.Two large, multisite RCTs and 13 smaller RCTs of high-risk women (8 good-quality) were included
Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia UTCAT2704, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia Clinical Question Is periodontitis a risk factor for development of preeclampsia during pregnancy? Clinical Bottom Line Research has shown that periodontal disease (...) contributes to the development of preeclampsia during pregnancy. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Sgolastra/2013 384 studies Meta-Analysis Key results This meta-analysis concluded that a relationship between pregnant women with periodontal disease (PD) and development of preeclampsia (PE) does indeed exist. Originally, 384 studies were reviewed; however, only 15 studies qualified for inclusion
Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms To evaluate two algorithms for prediction of preeclampsia in a population of nulliparous women in Norway.Prospective screening study.National Centre for Fetal Medicine in Trondheim, Norway.Five hundred and forty-one nulliparous women.The women were examined between 11(+0) and 13(+6) weeks with interviews for maternal characteristics and measurements of mean arterial (...) pressure, uterine artery pulsatility index, pregnancy-associated plasma protein A and placental growth factor. The First Trimester Screening Program version 2.8 by The Fetal Medicine Foundation (FMF) was compared with the Preeclampsia Predictor TM version 1 revision 2 by Perkin Elmer (PREDICTOR).Prediction of preeclampsia requiring delivery before 37 weeks, before 42 weeks and late preeclampsia (delivery after 34 weeks).The performance of the two algorithms was similar, but quite poor, for prediction
to prevent preeclampsia in women at high risk. N Engl J Med . 1998;338(11):701-5. 8. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ . 2013;347:f6564. 9. U.S. Preventive Services Task Force. Aspirin prophylaxis in pregnancy. In: Guide to Clinical Preventive Services . 2nd ed. Washington, DC: U.S. Department of Health and Human Services; 1996. 10. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre (...) States, 12% of maternal deaths are directly attributable to preeclampsia and eclampsia. However, morbidity is more common than mortality, and it is estimated that more than one third of severe obstetric complications are related to preeclampsia . Preeclampsia accounts for 15% of preterm births in the United States and is a leading cause of medically indicated preterm birth. Delivery is the only cure for preeclampsia . Early-onset preeclampsia is usually more severe and often requires preterm delivery
Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental (...) dysfunction in preeclampsia, with known low plasma concentrations in the disease.In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (<5th centile for gestation, Alere Triage assay) in women presenting with suspected preeclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a secondary analysis). The outcome was delivery for confirmed preeclampsia within 14 days. Of 625 women, 346 (55%) developed confirmed preeclampsia. In 287
Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. To estimate the contributions of biological aging, historical trends, and birth cohort effects on trends in pre-eclampsia in the United States.Population based retrospective study.National hospital discharge survey datasets, 1980-2010, United States.120 million women admitted to hospital for delivery.Temporal changes in rates of mild and severe pre-eclampsia in relation to maternal age, year of delivery, and birth (...) cohorts. Poisson regression as well as multilevel age-period-cohort models with adjustment for obesity and smoking were incorporated.The rate of pre-eclampsia was 3.4%. The age-period-cohort analysis showed a strong age effect, with women at the extremes of maternal age having the greatest risk of pre-eclampsia. In comparison with women delivering in 1980, those delivering in 2003 were at 6.7-fold (95% confidence interval 5.6-fold to 8.0-fold) increased risk of severe pre-eclampsia. Period effects
Fluid management in pre-eclampsia Intravenous fluid given to women with pre-eclampsia may be a necessary form of treatment; however, intravenous fluid therapy can also cause iatrogenic pulmonary oedema. The indications for the use of intravenous fluids, the titration of the amount of fluid given and the use of invasive monitoring have not been subject to adequate examination in randomised studies. Clinical experience, combined with available evidence and a reasoned approach are the basis
Mediators of the association between pre-eclampsia and cerebral palsy: population based cohort study. To test the hypothesis that pre-eclampsia is a risk factor for cerebral palsy mediated through preterm birth and being born small for gestational age.Population based cohort study.Clinical data from the Norwegian Cerebral Palsy Registry were linked with perinatal data prospectively recorded by the Medical Birth Registry of Norway.All singleton babies who survived the neonatal period during 1996 (...) -2006 (849 children with cerebral palsy and 616,658 control children).Cerebral palsy and cerebral palsy subtypes.Children exposed to pre-eclampsia had an excess risk of cerebral palsy (unadjusted odds ratio 2.5, 95% confidence interval 2.0 to 3.2) compared with unexposed children. Among children born at term (≥ 37 weeks), exposure to pre-eclampsia was not associated with an excess risk of cerebral palsy in babies not born small for gestational age (1.2, 0.7 to 2.0), whereas children exposed to pre
Economic assessment of screening for pre-eclampsia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. To assess the association of pre-eclampsia with later cardiovascular death in mothers according to their lifetime number of pregnancies, and particularly after only one child.Prospective, population based cohort study.Medical Birth Registry of Norway.We followed 836,147 Norwegian women with a first singleton birth between 1967 and 2002 for cardiovascular mortality through linkage (...) to the national Cause of Death Registry. About 23,000 women died by 2009, of whom 3891 died from cardiovascular causes. Associations between pre-eclampsia and cardiovascular death were assessed by hazard ratios, estimated by Cox regression analyses. Hazard ratios were adjusted for maternal education (three categories), maternal age at first birth, and year of first birthThe rate of cardiovascular mortality among women with preterm pre-eclampsia was 9.2% after having only one child, falling to 1.1% for those
Antioxidants for preventing preeclampsia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia The purpose of this study was to evaluate the performance of the 12-hour urine protein >165 mg and protein:creatinine ratio >0.15 for the prediction of 24-hour urine protein of ≥300 mg in patients with suspected preeclampsia.We performed a prospective observational study of 90 women who had been admitted with suspected preeclampsia. Protein:creatinine ratio and 12
UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. UPDATED: Placental growth factor (...) based tests for the diagnosis of pre-eclampsia. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biomarkers; Pre-Eclampsia; Pregnancy Proteins; Pregnancys Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics
Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis Diagnostic accuracy of spot urinary protein (...) and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD CRD summary The authors concluded that protein to creatinine ratio had promising diagnostic value for significant proteinuria in women with suspected pre-eclampsia, but its use in clinical practice was unclear. There was insufficient evidence on albumin to creatinine ratio
DELFIA Xpress PlGF kit antenatal screening test to predict risk of pre-eclampsia DELFIA® Xpress PlGF kit antenatal screening test to predict risk of pre-eclampsia DELFIA® Xpress PlGF kit antenatal screening test to predict risk of pre-eclampsia NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. DELFIA® Xpress PlGF kit antenatal (...) screening test to predict risk of pre-eclampsia. Birmingham: National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biomarkers; Pre-Eclampsia; Predictive Value of Tests; Pregnancy; Prenatal Diagnosiss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health
Pulmonary artery flow catheters for directing management in pre-eclampsia. Gestational hypertension and pre-eclampsia can cause fluid shifts. Pulmonary oedema and renal failure can result from these shifts. Fluid management is crucial in managing pre-eclampsia, especially in the context of pulmonary oedema and renal failure. Pulmonary artery catheterisation may be a method of effectively monitoring fluid status and thus aid in the management of renal failure and pulmonary oedema in the context (...) of pre-eclampsia.To assess the safety and efficacy of pulmonary flow catheters in women with severe pre-eclampsia in preventing and managing of renal failure and pulmonary oedema or both.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2012).Randomised trials evaluating the use of the pulmonary artery catheterisation in the management of pre-eclamptic and eclamptic antepartum, intrapartum and postpartum women.We did not identify any randomised controlled
Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays Placental growth factor and soluble Fms-like tyrosine kinase-1 may be potential diagnostic markers of preeclampsia. We compared performances of 2 immunoassays, the Triage placental growth factor assay and the Elecsys soluble Fms-like tyrosine kinase-1/placental growth factor ratio in diagnosing preeclampsia.A single site, case-control study of 44 patients with preeclampsia (...) and 84 matched normal pregnant controls. Samples were collected at the time of diagnosis. Assays were performed according to product inserts.Both assays had optimal performance in diagnosing early-onset preeclampsia with area under the receiver operating characteristic curves of 0.99 (Triage: 100% sensitivity, 96% specificity; Elecsys: 64% sensitivity, 100% specificity for early-onset preeclampsia). Reassignment of the Elecsys cutoff for a positive test based on receiver operating characteristic
Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia WHO | WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia Access Search Search the Navigation Language Sexual and reproductive health Menu WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia Authors : WHO Publication details Number of pages : 38 Publication date : 2011 Languages : English, French, Portuguese, Spanish, Russian ISBN : 978 92 4 154833 5 Downloads (...) pdf, 859 KB 2018 UPDATES 2 recommendations, 75 pages, pdf 652Kb 3 recommendations, 31 pages, pdf 394Kb 1 recommendation, 44 pages, pdf 487Kb Other language versions (2011) About the guidelines Improving care for women during pregnancy and around the time of childbirth to prevent and treat pre-eclampsia and eclampsia is a necessary step towards the achievement of the health targets of the Sustainable Development Goals (SDGs). Efforts to prevent and reduce morbidity and mortality due